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Abstract  
AIM: Hidradenitis suppurativa (HS) is a chronic inflammatory disease, commonly characterized by painful, deep 
dermal abscesses and chronic draining sinus tracts. Recently, laser and light-based therapies have become more 
commonly used in the management of HS.  
MATERIAL AND METHODS: We report 20 HS patients treated with a 1064 nm wavelength, emitted from a diode 
laser, launched in an optical fibre through intracavitary modalities.  
RESULTS: Each patient underwent four laser sessions, one every two weeks. we recorded a significative 
reduction (31%) of Sartorius score from 28.55 ± 13.04 to 19.75 ± 12.29 after 4 laser sessions (p < 0.05). No one 
has had a worsening of the disease.  
CONCLUSION: Intralesional diode laser 1064 nm can be a good treatment option for patients with moderate and 
localized hidradenitis suppurativa, because it is minimally invasive, doesn’t have significant complications and 
provides a rapid post-treatment recovery. 
 
 
 
 
 
 
 
 
Introduction 
 
Hidradenitis suppurativa (HS) is a chronic 
inflammatory disease, commonly characterized by 
painful, deep dermal abscesses and chronic draining 
sinus tracts [1][2]. Classically, pharmacologic agents 
ranging from antibiotics, isotretinoin, acitretin, anti-
androgens and various biological agents such as 
Adalimumab and Infliximab, and surgical therapies 
have been effective for reducing lesion activity, and 
inflammation and have been shown to be helpful to 
treat the disease [3][4]. In several cases, these 
medications provide only transitory results, and they 
cannot act in the prevention of future recurrences or 
disease progression. No single agent has been 
proved to show overwhelmingly positive outcomes 
[5][6][7]. Recently, laser and light-based therapies 
have become more commonly used in the 
management of HS. Different kinds of laser-based 
therapies have been studied over the last years. The 
laser can act in 2 different modalities, selective and 
ablative. Intense Pulsed Light (IPL) and lasers like 
NdYag, Alexandrite and Diode act selectively and are 
considered the most useful in Hurley stage I-II, 
because of their ability to reduce the number of hair 
follicles, sebaceous glands, and consequently to 
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reduce the bacterial load; the CO2 laser acts in 
ablative modality and seems to be more useful in 
Hurley stage II-III [8][9].  
We report 20 HS patients treated with a 1064 
nm wavelength, emitted from a diode laser, launched 
in an optical fibre through intracavitary modalities. 
 
 
Materials and Methods 
 
Twenty patients were recruited at the 
University Federico II of Naples, Section of 
Dermatology, from May 2016 to January 2017. The 
authors declare that their research complied with the 
guidelines for human studies and welfare regulation 
and the subjects participating in the research have 
given their informed consent. All patients were 
recommended to a wash-out period from any topical 
and systemic medications.  
We excluded patients with significant 
comorbidities and those who were pregnant.  
Each patient underwent four laser sessions, 
one every two weeks. 
Hurley stage, Sartorius score and PGA were 
registered before starting laser therapies and at the 
end of these (after eight weeks - 4 sessions). 
Responses were classified as complete (improved by 
65% or more), good (between 40% and 65%), partial 
(between 15% and 40%) and no response (less than 
15%). Hidradenitis Suppurativa Clinical Response 
(HiSCR) was used as another tool to evaluate clinical 
response to the treatment. 
Dermatology Quality of Life Index (DLQI) was 
recorded to judge the impact on the quality of life of 
HS patients before starting treatment and two weeks 
after the end of the study.  
A diode laser with a wavelength of 1064nm in 
pulsed operation, launched in fibre from 300-600 μm 
(coated glass fibre polycarbonate) was used for the 
clinical study. This laser was supplied by Eufoton. 
A standard energy fluence of 250 J/cm
2
 has 
been used, employing different diameters fibres 
depending on the type of the lesion and its anatomical 
localisation. In any case, the energy thresholds of 
2500J on 10 cm
2
 were never exceeded. 
Energy is delivered by a micro-variable pulse 
train from 150 to 350 milliseconds by the selected 
power energy. 
The fibre size (400-600 microns) and the 
energy power selected (6 - 8 - 10 Watts) took into 
account the physiological condition of the lesion and 
the surrounding skin. 
Local anaesthetic (Mepivacaine hydrochloride 
with epinephrine) was injected directly into the 
anatomical area involved by the disease, at the 
superficial subcutaneous plane.  
A 30 G needle was used, and approximately 1 
ml anaesthetic solution per cm
2
 was administered. 
The infiltration was practised until obtaining 
tumescence of the concerned area. This procedure, 
particularly effective in controlling pain, was made 
possible thanks to the low water absorption for the 
wavelength of the laser.  
Performed anaesthesia, the intervention 
included the identification of the orifices of suppurating 
lesions, the introduction of the optical fibre inside them 
and the subsequent decontamination-denaturing by 
the direct action of the laser on the pathological 
tissue. From the day of the laser-surgical procedure, 
all patients were subjected to an oral antibiotic 
treatment with azithromycin 500 mg once daily for 
three days. Four treatment sessions were performed, 
one every two weeks. 
 
 
Results 
 
The open clinical study was conducted in 
twenty patients aged between 18 and 44 years (mean 
age 26.6 ± 7.84) suffering from HS; anatomical sites 
involved by HS were the axillae, the groin, buttocks, 
the brisket and the infra-mammary fold (Table 1).  
Table 1: The open clinical study was conducted in twenty 
patients aged between 18 and 44 years (mean age 26.6 ± 7.84) 
suffering from HS; anatomical sites involved by HS were the 
axillae, the groin, buttocks, the brisket and the infra-mammary 
fold 
 
50% of patients had a Hurley stage I, while 
the remaining subjects had a Hurley stage II; no 
patient with Hurley stage III was recruited. 
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All results are showed in Table 2. In 
summary, we recorded a significative reduction (31%) 
of Sartorius score from 28.55 ± 13.04 to 19.75 ± 12.29 
after 4 laser sessions (p < 0.05).  
Table 2: Fifty percentages (50%) of patients had a Hurley stage 
I, while the remaining subjects had a Hurley stage II; no patient 
with Hurley stage III was recruited. We recorded a significative 
reduction (31%) of Sartorius score from 28.55 ± 13.04 to 19.75 ± 
12.29 after four laser sessions (p<0.05). In particular, we 
registered the following clinical response: 1 patient with a 
complete response (improved by 65% or more); 7 patients with 
a good response (between 40% and 65%); 10 patients with a 
partial response (between 15% and 40%); 2 no response (less 
than 15%). No one has had a worsening of the disease. HiSCR, 
which is considered a useful tool in detecting changes after 
treatment, was achieved in 13 patients (65% of patients). Most 
notably HiSCR was achieved in 60% of patients with Hurley II 
and 80% patients with Hurley I 
 
In particular, we registered the following 
clinical response: 
 One patient with a complete response 
(improved by 65% or more) 
 Seven patients with a good response 
(between 40% and 65%) 
 Ten patients with a partial response (between 
15% and 40%) 
 Two no response (less than 15%). 
No one has had a worsening of the disease. 
HiSCR, which is considered a useful tool in 
detecting changes after treatment, was achieved in 13 
patients (65% of patients). Most notably HiSCR was 
achieved in 60% of patients with Hurley II and 80% 
patients with Hurley I.  
In parallel with clinical improvement, we 
registered a marked improvement in the quality of life 
of patients undergoing the treatment, showed by DLQI 
values reduction (p = 0.0307). 
Most patients (18 of 20) tolerated the 
procedure without any symptoms. Adverse effects 
included postoperative pain, erythema, and mild 
swelling. One patient complained of fever and an 
influenza-like illness, which resolved itself. Serious 
adverse side effects, suppuration or infections did not 
occur. 
 
 
Discussion 
 
In several cases of HS patients, medical 
therapy is unsatisfactory, and it is very difficult to 
identify the way to stop the progression of the 
disease.  
Laser treatment could represent an alternative 
therapy for the early stages of HS. Selective lasers, 
such as NdYag, Alexandrite and Diode, can be very 
useful in the early stage of disease [9][10]. On the 
other hand, ablative lasers are usually used in the 
worst cases. There are very few data in literature 
focused on the use of diode laser to improve 
symptoms of HS. The rational of the diode laser can 
be explained by the reduction in the number of hair 
follicles.  
Downs et al. achieved a partial improvement 
of hidradenitis suppurativa with a sweating reduction 
following four treatments with a 1450 nm diode laser 
[11]. 
In 2011 Sehgal et al. reported favourable 
outcomes in a case report of Axillary HS using diode 
laser 800 nm after six sessions at an interval of 3 – 4 
months (energy 34 J/cm 2, pulse duration 110 – 140 
ms) [12]. 
Valladares-Narganes LM and colleagues 
reported twenty-seven patients affected by 
hidradenitis suppurativa treated with intralesional 
photodynamic therapy using a diode laser attached to 
an optical cable. They recorded very good results in 
almost 80% patients with best results achieved in 
isolated fistulas, axillary, sacral and breast locations, 
where the majority of cases are found [13]. 
A histopathological survey demonstrated the 
mechanism of action of the 1064 nm Nd: Yag laser in 
the treatment of HS: this type of laser penetrates the 
follicular unit and, through a selective 
photothermolysis, causes the destruction of organized 
inflammatory lesions in the superficial to mid dermis. 
The wavelength 1064 nm in the near-infrared 
electromagnetic spectrum selectively targets hair 
shafts and follicles via absorption by the melanin 
chromophore [15].  
The wavelength used in our research can 
perform similarly and to get stackable results. 
Recently has been published an experience on 7 HS 
patients treated with photodynamic therapy with 
intralesional methylene blue and a 635 nm light-
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emitting diode lamp. After six months, five patients 
(71%) maintained remission of the disease in the 
treated area. Photodynamic therapy has been used 
for its ability to reduce bacterial biofilms, which is a 
common finding in hidradenitis lesions [16]. 
Also, some published clinical and 
histopathological data suggested that the Nd: YAG 
microsecond pulsed laser in optical glass fiber was 
able to sterilize by selective photoantisepsis all the 
affected areas and was also able to decrease the 
inflammation in the surrounding tissue [17]. Laser 
treatment proposed in our survey conjugate the laser 
action (1064 nm wavelength able to destroy follicular 
unit and organized inflammatory lesions) with the 
intralesional application of the light that allows 
reaching different depths (from the superficial to mild 
dermis). Treatment efficacy has been proved by the 
reduction of Sartorius score and by HiSCR. It is 
important to underline that only 4 patients had a 
marginal improvement and no one got worse. 
Moreover, in comparison to surgery, our laser 
is less invasive; it has been performed under local 
anaesthesia and therefore does not require 
hospitalization. Also, the treatment is well tolerated by 
patients with very few adverse events,  
which don’t limit patient's life (days of absence from 
work). This laser can be a good alternative for those 
patients that are not responsive to medical therapy. It 
can be performed in patients undergoing biologic 
treatment because it doesn’t increase the risk of 
immunosuppression and does not induce 
autoantibodies formation, therefore can repeatedly be 
used without complications.  
The main restrictions of our survey are the 
small sample, but it is important to underline that 
prevalence remains uncertain and HS is frequently 
misdiagnosed as a simple infection. 
In conclusion, the intralesional Diode laser 
1064 nm can be a good treatment option for patients 
with moderate and localized hidradenitis suppurativa, 
because it is minimally invasive, doesn’t have 
significant complications and provides a rapid post-
treatment recovery.  
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